STOCK TITAN

Illumina Inc - ILMN STOCK NEWS

Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.

Illumina Inc (ILMN), a global leader in genomic sequencing technologies, provides critical tools advancing precision medicine and life science research. This dedicated news hub offers investors and industry professionals centralized access to official press releases, financial disclosures, and strategic updates directly from the company.

Track developments across key areas including quarterly earnings, sequencing platform innovations, and global health partnerships. Stay informed about regulatory milestones, product launches, and collaborations shaping the future of genomic analysis. Bookmark this page for unfiltered access to Illumina's latest announcements, enabling data-driven decisions in the rapidly evolving biotechnology sector.

Rhea-AI Summary

Illumina (NASDAQ: ILMN) has announced a multi-year partnership with Agendia to co-develop in vitro diagnostic tests for oncology, specifically targeting breast cancer. This collaboration aims to enhance the use of next-generation sequencing for decentralized testing. Agendia's MammaPrint test, which predicts breast cancer recurrence risk and is FDA-cleared, will be the first decentralized NGS-based test of its kind. The partnership seeks to leverage both companies' expertise to improve patient care and management globally.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.98%
Tags
partnership
-
Rhea-AI Summary

Illumina has partnered with Boehringer Ingelheim to develop companion diagnostics for its oncology programs aimed at enhancing precision medicine for advanced cancer patients. The collaboration will fast-track therapy selection by adding companion diagnostic claims to Illumina's TruSight Oncology 500 assay. This initiative emphasizes the use of comprehensive genomic profiling to identify patients suited for novel therapies. Joydeep Goswami from Illumina expressed enthusiasm over the long-term partnership, highlighting its potential in unlocking new biomarkers critical for cancer treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.98%
Tags
partnership
-
Rhea-AI Summary

Illumina (NASDAQ: ILMN) reported a strong financial performance for 2021, with fourth-quarter revenue at approximately $1.190 billion (+25% YoY) and a full-year revenue of $4.517 billion (+39% YoY). The company anticipates 2022 revenue of $5.15-$5.24 billion, reflecting a growth of 14-16%. CEO Francis deSouza emphasized new partnerships in oncology and advancements in genomic technologies, including early cancer detection tests and innovative sequencing methods. These initiatives aim to enhance healthcare and drive further market penetration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.98%
Tags
none
Rhea-AI Summary

GRAIL has partnered with the OHSU Knight Cancer Institute to offer the advanced Galleri blood test, which aims to detect over 50 types of cancer early. The pilot program will be available to eligible patients, enhancing cancer detection methods significantly, as traditional screenings only cover a limited number of cancer types. Galleri's low false positive rate and high accuracy in identifying cancer origins are crucial in the fight against cancer, which claims over 600,000 lives annually in the U.S.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
none
-
Rhea-AI Summary

GRAIL announced a collaboration with Premier, Inc.'s PINC AI to enhance patient access to Galleri, a multi-cancer early detection blood test. This partnership aims to integrate AI-based alerts for clinicians to identify patients at elevated cancer risk. Community Health Network will pilot these alerts. The Galleri test can detect over 50 cancer types through a single blood draw, improving early detection and treatment outcomes. GRAIL emphasizes the importance of early cancer detection to increase survival rates, as many cancers are diagnosed late when treatment options are limited.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
partnership
-
Rhea-AI Summary

Illumina (NASDAQ: ILMN) has announced a co-development agreement with SomaLogic to integrate the SomaScan® Proteomics Assay with its next-generation sequencing (NGS) platforms. This collaboration aims to enhance the high throughput proteomics market, enabling researchers to analyze thousands of samples for over 10,000 protein targets efficiently and cost-effectively. The partnership taps into the estimated $50 billion proteomics market, allowing Illumina to utilize its extensive NGS technology to boost multiomic research capabilities. Discussions regarding this partnership will take place at the J.P. Morgan Healthcare Conference on January 10, 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3%
Tags
partnership
Rhea-AI Summary

Illumina (NASDAQ: ILMN) announced that its executives will present at the J.P. Morgan Annual Healthcare Conference on January 10, 2022. The presentation is set for 12:45 PM PT, followed by a Q&A session starting around 1:05 PM PT. Interested parties can access the live webcast via the Investor Info section on illumina.com. A replay will be available for at least 30 days post-event. Illumina continues to lead in DNA sequencing and array-based technologies, impacting various sectors such as life sciences and clinical markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.62%
Tags
conferences
-
Rhea-AI Summary

Illumina (NASDAQ: ILMN) partners with Gretel.ai to create privacy-protected synthetic genomic data. This collaboration aims to enhance medical research by providing immediate access to statistically accurate genomic datasets without lengthy approval processes. The partnership demonstrates new use cases for synthetic data in genomics, promising advancements in drug discovery and genetic disorder treatment. With a focus on compliance with GDPR and CCPA, this initiative is poised to accelerate DNA sequencing analysis and medical breakthroughs for various health challenges, including COVID-19.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
partnership
-
Rhea-AI Summary

Illumina (NASDAQ:ILMN) announces support for a national precision medicine study in Norway called IMPRESS-Norway. This initiative aims to evaluate blood-based comprehensive genomic profiling (CGP) for selecting cancer therapies and assess its cost-effectiveness in the public healthcare system. The study will involve a sub-study of 500 patients, comparing solid tissue biopsies with blood samples. If successful, this could make less invasive CGP testing more accessible, enhancing patient participation in clinical trials. The analysis will utilize Illumina's DRAGEN software.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.23%
Tags
none
Rhea-AI Summary

GRAIL, LLC has partnered with Alignment Health Plan to provide Medicare Advantage members in California and North Carolina access to Galleri®, a multi-cancer early detection blood test. Starting January 1, 2022, new and existing members can obtain the test, which detects over 50 cancers, many of which lack standard screenings. The initiative aims to enhance cancer detection among seniors, thereby potentially reducing late-stage diagnoses.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.26%
Tags
partnership
Illumina Inc

Nasdaq:ILMN

ILMN Rankings

ILMN Stock Data

11.27B
157.95M
0.3%
105.88%
4.11%
Diagnostics & Research
Laboratory Analytical Instruments
Link
United States
SAN DIEGO